Selected article for: "administration route timing and route timing"
Author: De Clercq, Erik
Title: Remdesivir: Quo vadis?()
  • Cord-id: s6fvrd4b
  • Document date: 2021_10_19
    • ID: s6fvrd4b
    Snippet: Remdesivir (GS-5734, Veklury®) has remained the only antiviral drug formally approved by the US FDA for the treatment of Covid-19 (SARS-CoV-2 infection). Its key structural features are the fact that it is a C-nucleoside (adenosine) analogue, contains a 1′-cyano function, and could be considered as a ProTide based on the presence of a phosphoramidate group. Its antiviral spectrum and activity in animal models have been well established and so has been its molecular mode of action as a delayed
    Document: Remdesivir (GS-5734, Veklury®) has remained the only antiviral drug formally approved by the US FDA for the treatment of Covid-19 (SARS-CoV-2 infection). Its key structural features are the fact that it is a C-nucleoside (adenosine) analogue, contains a 1′-cyano function, and could be considered as a ProTide based on the presence of a phosphoramidate group. Its antiviral spectrum and activity in animal models have been well established and so has been its molecular mode of action as a delayed chain terminator of the viral RdRp (RNA-dependent RNA polymerase). Its clinical efficacy has been evaluated, but needs to be optimized with regard to timing, dosage and duration of treatment, and route of administration. Safety, toxicity and pharmacokinetics need to be further addressed, and so are its potential combinations with other drugs such as corticosteroids (i.e. dexamethasone) and ribavirin.

    Search related documents:
    Co phrase search for related documents
    • active metabolite and acute respiratory failure: 1
    • active metabolite and additional day: 1
    • active metabolite and adenosine analogue: 1
    • active metabolite and administration route: 1, 2
    • active metabolite and loading dose: 1, 2, 3, 4
    • active metabolite and low potential: 1, 2, 3, 4
    • active triphosphate metabolite and adenosine analogue: 1
    • active triphosphate metabolite and administration route: 1
    • active triphosphate metabolite and loading dose: 1, 2, 3
    • active triphosphate metabolite and low potential: 1, 2, 3
    • acute kidney injury and additional day: 1
    • acute kidney injury and administration route: 1
    • acute kidney injury and loading dose: 1
    • acute kidney injury and low potential: 1
    • acute respiratory failure and additional day: 1, 2
    • acute respiratory failure and administration route: 1
    • acute respiratory failure and loading dose: 1
    • acute respiratory failure and low potential: 1, 2, 3, 4